Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Infect Dis Now ; 52(2): 107-109, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-34242839

RESUMEN

We report a French case of tularemic meningitis - the second to be thoroughly described - and discuss the existing literature. The patient is a 64-year-old man with no medical history, who developed fever, cutaneous symptoms, and swollen lymph nodes within a week after a hunt. He was then diagnosed with meningitis caused by Francisella tularensis subsp. holarctica. Healing was quickly achieved ad integrum within 3 weeks with a course of ciprofloxacin. We discuss the existing literature about this specific issue, and try to shine a light on the superior efficacy and lesser toxicity of quinolones compared to the historical treatment.


Asunto(s)
Francisella tularensis , Meningitis , Quinolonas , Tularemia , Fiebre , Humanos , Masculino , Persona de Mediana Edad , Quinolonas/uso terapéutico , Tularemia/diagnóstico , Tularemia/tratamiento farmacológico
2.
Rev Pneumol Clin ; 73(3): 135-139, 2017 Jun.
Artículo en Francés | MEDLINE | ID: mdl-28412028

RESUMEN

INTRODUCTION: The search for mutations epidermal growth factor receptor (EGFR) has changed the therapeutic approach and prognosis of non-small cell lung cancer (NSCLC). The effectiveness of tyrosine kinase inhibitors (TKI) has been demonstrated orally in patients with EGFR mutation. We report the case of a patient for whom treatment with TKI was started effectively in a Critical Care Unit. OBSERVATION: A patient of 59 years is followed for a stage IV lung adenocarcinoma with metastases in liver, brain, adrenal, lung and pleura. After a first course of chemotherapy (cisplatin-gemcitabine), the patient presents a multi-factorial acute respiratory distress. Due to an EGFR mutation, transfer to intensive care is decided then orotracheal intubation with mechanical ventilation. It is decided to initiate treatment with erlotinib via nasogastric tube. The evolution will be marked by a tumor response leading to a favorable issue. CONCLUSIONS: This case shows the value of initiate TKI despite hospitalization in Intensive Care Unit and highlights the question of the transfer in ICU patients with EGFR mutation.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Cuidados Críticos , Receptores ErbB/genética , Clorhidrato de Erlotinib/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/genética , Femenino , Humanos , Unidades de Cuidados Intensivos , Neoplasias Pulmonares/genética , Persona de Mediana Edad , Mutación , Resultado del Tratamiento
4.
Rev Mal Respir ; 32(1): 52-7, 2015 Jan.
Artículo en Francés | MEDLINE | ID: mdl-25618205

RESUMEN

INTRODUCTION: The small cell lung cancer (SCLC) is a rapidly progressive malignancy with a poor prognosis. Its chemosensitivity mandates prompt treatment. Hyponatremia occurs frequently in patients with small cell lung cancer due to the syndrome of inappropriate antidiuretic hormone (SIADH). We report a case of severe hyponatremia induced by chemotherapy that required management in intensive care. OBSERVATION: A 68-year-old patient was undergoing treatment for small cell cancer, invading the right lung. On the second day of the first cycle of treatment (cisplatine-vepeside), the patient became comatose and required transfer to an intensive care unit. The coma was due to severe hyponatremia (107 mmol/L) and improved with specific treatment. The patient had similar episodes on the second day of each chemotherapy treatment but with less and less severe clinical manifestations. Hyponatremia due to chemotherapy in SCLC is not commonly known; a relation between hyponatremia intensity and the tumor size is suspected. CONCLUSION: This clinical case highlights the possibility of severe hyponatremia during small cell lung cancer chemotherapy. Hyponatremia may be related to the reduction in tumor size. Monitoring of electrolytes on day 2 of chemotherapy is advised.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Pequeñas/tratamiento farmacológico , Hiponatremia/etiología , Síndrome de Secreción Inadecuada de ADH/etiología , Neoplasias Pulmonares/tratamiento farmacológico , Anciano , Carcinoma de Células Pequeñas/complicaciones , Cisplatino/administración & dosificación , Coma/etiología , Etopósido/administración & dosificación , Humanos , Síndrome de Secreción Inadecuada de ADH/sangre , Neoplasias Pulmonares/complicaciones , Masculino , Recurrencia , Tomografía Computarizada por Rayos X
5.
Int J Tuberc Lung Dis ; 16(3): 373-5, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22230257

RESUMEN

Lymph node tuberculosis (LNTB) is the most frequent form of extra-pulmonary tuberculosis (TB). Randomised, controlled trials have convincingly demonstrated that 6 months of chemotherapy is sufficient for most drug-susceptible LNTB. We performed a retrospective, multicentric study from 1997 to 2010 to describe factors associated with prolonged anti-tuberculosis treatment in patients with LNTB. Of 126 patients diagnosed with LNTB, 22 (17.5%) were human immunodeficiency virus (HIV) infected. The median treatment duration was 9 months (interquartile range, 6-12). Treatment was significantly longer in patients with HIV (P < 0.01), additional sites of TB (P < 0.01) or weight loss (P = 0.04). Factors independently associated with excessively lengthy treatment were HIV co-infection and the presence of other TB foci.


Asunto(s)
Antituberculosos/uso terapéutico , Infecciones por VIH/complicaciones , Tuberculosis Ganglionar/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antituberculosos/administración & dosificación , Esquema de Medicación , Femenino , Estudios de Seguimiento , Infecciones por VIH/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Tuberculosis/epidemiología , Tuberculosis/fisiopatología , Pérdida de Peso , Adulto Joven
7.
Rev Mal Respir ; 27(1): 37-41, 2010.
Artículo en Francés | MEDLINE | ID: mdl-20146950

RESUMEN

INTRODUCTION: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) has recently been shown to be an accurate modality in the diagnosis and staging of mediastinal lymph node metastases. This procedure takes significantly longer than a conventional bronchoscopy and may therefore cause more discomfort. Since its introduction into respiratory practice in France, several airway management strategies have been used. PATIENTS AND METHODS: Both anaesthesia care and procedural sedation services share the goals of providing the patient with comfort during a potentially distressing procedure while also ensuring that the operating physician has an acceptable working environment. Historically, anaesthesiologists have applied the expertise gained in managing anaesthesia for major surgery to sedation care for minor procedures. While the supply of anaesthesiologists and anaesthetists has shown only a modest increase, the growth in minimally invasive procedures has been exponential in recent years. To investigate this further, we performed a retrospective study of the use of general anaesthetic with ventilation by a laryngeal mask during EBUS, which we have adopted in our unit. RESULTS: Sixty-three patients were included in the study. In 41 a laryngeal mask was used and in 22 the examination was performed under local anaesthetic alone. Eighty-seven percent of procedures were informative with cells from lymph nodes obtained (89% from examinations using laryngeal mask with a mean of 3.8 passes and 86% with sedation alone with a mean of 2.9 passes). In 45 cases (78%) it was possible to avoid mediastinoscopy. CONCLUSION: It was possible to establish a secure airway and maintain oxygenation with the laryngeal mask during bronchoscopy without any reduction in the success of the procedure.


Asunto(s)
Anestesia General , Biopsia con Aguja , Broncoscopía , Neoplasias Pulmonares/patología , Metástasis Linfática/patología , Neoplasias del Mediastino/patología , Neoplasias del Mediastino/secundario , Ultrasonografía Intervencional , Anciano , Anestesia Local , Femenino , Humanos , Máscaras Laríngeas , Ganglios Linfáticos/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Evaluación de Procesos y Resultados en Atención de Salud , Estudios de Tiempo y Movimiento
8.
Med Mal Infect ; 38(9): 465-70, 2008 Sep.
Artículo en Francés | MEDLINE | ID: mdl-18718729

RESUMEN

UNLABELLED: The main characteristics of clindamycin are adequate for treatment of osteoarticular infections (OAI): good bone diffusion, broad spectrum of antibacterial activity and oral use. METHOD: A number of 61 patients was included in an observational retrospective study of efficacy and tolerance. RESULTS: Prosthetic infections accounted for 50.8% of the cases and chronic osteitis for 36.1%. The causative micro-organisms were Staphylococci (72.2%) and Streptococci (15.3%); 86.5% of these strains were susceptible to erythromycin, 9.6% were erythromycin resistant and susceptible to lincomycin. Clindamycin was associated with either ofloxacine, rifampicin, or teicoplanin in 88.5% and the average course duration was 101 days. A surgical procedure was performed in 84% of cases. Complete cure was obtained in 91.1% at 18 months of follow up. Only one cutaneous rash and one Clostridium difficile-associated diarrhea occurred. The other adverse effects were gastrointestinal in 36%, cutaneous in 6.6%, and hematological in 1.6%, but did not lead to discontinuation of therapy. CONCLUSION: Clindamycin can be used in OAI in association with or as an alternative to rifampicin, fluoroquinolones, or glycopeptides according to microbiological data.


Asunto(s)
Antibacterianos/uso terapéutico , Enfermedades Óseas/tratamiento farmacológico , Enfermedades Óseas/microbiología , Clindamicina/uso terapéutico , Artropatías/tratamiento farmacológico , Artropatías/microbiología , Osteítis/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/efectos adversos , Enfermedades Óseas/etiología , Clindamicina/administración & dosificación , Diarrea/inducido químicamente , Quimioterapia Combinada , Tolerancia a Medicamentos , Femenino , Humanos , Artropatías/etiología , Masculino , Persona de Mediana Edad , Ofloxacino/uso terapéutico , Osteítis/etiología , Implantación de Prótesis/efectos adversos , Estudios Retrospectivos , Rifampin/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/etiología , Procedimientos Quirúrgicos Operativos/efectos adversos , Teicoplanina/uso terapéutico
9.
Rev Mal Respir ; 25(3): 344-6, 2008 Mar.
Artículo en Francés | MEDLINE | ID: mdl-18449103

RESUMEN

INTRODUCTION: Post pneumonectomy infection is a well-described surgical complication. Treatment usually involves thoracostomy and requires local treatments. We report here an unusual complication of this situation. CASE REPORT: A 62 year old man had a pneumonectomy for non-small cell lung cancer. Following this he required a thoracostomy to treat a thoracic empyema and this was treated with local anti-septic agents. Subsequently he developed asthenia and a diagnosis of hyperthyroidism was made secondary to local disinfectant treatment with iodine agents. CONCLUSIONS: We describe an original case of thyroxicosis occurring in a patient following treatment for post-pneumonectomy empyema. We would recommend monitoring thyroid function in this context.


Asunto(s)
Antiinfecciosos Locales/efectos adversos , Astenia/inducido químicamente , Hipertiroidismo/inducido químicamente , Povidona Yodada/efectos adversos , Toracostomía/efectos adversos , Antiinfecciosos Locales/administración & dosificación , Empiema Pleural/cirugía , Humanos , Masculino , Persona de Mediana Edad , Neumonectomía , Povidona Yodada/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...